DOCSLIB.ORG

Familial Hyperkalemic Hypertension

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Familial Hyperkalemic Hypertension Disease of the Month Familial Hyperkalemic Hypertension Juliette Hadchouel,* Ce´line Delaloy,* Se´bastien Faure´,† Jean-Michel Achard,† and Xavier Jeunemaitre* *Colle`ge de France, Paris; INSERM U36, Paris; AP-HP, Department of Genetics, Hoˆpital Europe´en Georges Pompidou; University Paris-Descartes, Faculty of Medicine, Paris, France; and †Division of Nephrology and Department of Physiology, Limoges University Hospital, Limoges, France J Am Soc Nephrol 17: 208–217, 2006. doi: 10.1681/ASN.2005030314 amilial hyperkalemic hypertension (FHHt) syndrome biochemical abnormalities and age or BP, which seemed to (1,2), also known as Gordon syndrome (3) or pseudohy- depend primarily on age in affected individuals (11). This F poaldosteronism type 2 (4), is a rare inherited form of phenotypic variability, associated with sensitivity to thia- low-renin hypertension associated with hyperkalemia and hy- zides—which are widely used in hypertension—and with a low perchloremic metabolic acidosis in patients with a normal GFR probability of this rare disease’s being recognized by most (OMIM no. 145260). This monogenic form of arterial hyperten- doctors may have led to an underestimation of its frequency. sion has excited new interest since the discovery of a new, The mode of inheritance of the disease is consistent with unsuspected molecular pathway that is responsible for both the autosomal dominant transmission in most, if not all, of the biochemical abnormalities and the increase in BP observed. pedigrees reported. However, we have identified two families Genetic analysis has led to the identification of mutations in in which the parents of the affected individuals were first two genes that belong to a new family of kinases, the WNK cousins, suggesting possible autosomal recessive transmission. family. Although the physiologic functions of these kinases and This would provide further evidence of the genetic heteroge- the pathophysiology of FHHt are not completely solved, these neity of the disease. Indeed, three loci have already been im- results have opened up major new avenues toward under- plicated in this disease, and additional loci probably are re- standing the regulation of ion handling in the aldosterone- sponsible for the same apparent phenotype. Genomic analysis sensitive nephron. of kindreds with FHHt revealed no linkage with SLC12A3, encoding the thiazide-sensitive NaCl co-transporter (NCC) (12 Chasing the Gene and our own data). In 1997, Lifton’s group at Yale University Phenotypic and Genetic Heterogeneity demonstrated locus heterogeneity of the trait, with a multilocus Since the first description of the disease by Paver and Pauline logarithm of odds score of 8.1 for linkage to two loci: a 20- to in 1964 (1), approximately 50 other cases and families have been 33-cM interval on chromosome 1q31-q42 (PHA2A locus) and a reported (5,6). The original case was a 15-yr-old boy with severe 21- to 43-cM linkage interval on chromosome 17p11-q21 hypertension (180/120 mmHg) and very high potassium levels (PHA2B locus) (13). Our analysis of a large French pedigree led (7.0 to 8.2 mmol/L). Detailed analyses using different diets and to the identification of a new locus on chromosome 12p13.3 pharmacologic stimuli showed that the kidney was probably (14). We were able to exclude linkage with the previously involved but that the renal tubule reacted normally to an acid identified loci and with SLC12A3 in three other French kin- load and to carbonic anhydrase inhibitor. Sensitivity to thiazide dreds, demonstrating the involvement of at least one other gene diuretics was reported a few years later in unrelated, affected in the disease (15). Thus, at least four different genes are re- individuals (2,7). Gordon’s group reported their first case in sponsible for FHHt, suggesting that this syndrome is actually a 1970 (8) and helped to demonstrate the existence of a unifying set of related disorders (Table 1). Two of these genes were syndrome (5). High levels of variability, in terms of age at identified recently (16). diagnosis, which may vary from the first few weeks of life (9) until late in adulthood (10), have been reported in sporadic and Identification of the WNK1 and WNK4 Genes familial cases. We observed a similarly high level of variability A fruitful collaboration with Lifton’s group led to the iden- in the first 14 FHHt families studied at our center (6), with the tification of deletions and missense mutations in two genes age at diagnosis of index cases ranging from 7 mo to 39 yr. An encoding members of a novel family of serine/threonine ki- analysis of the affected and unaffected individuals of our larg- nases. These two genes, WNK1 and WNK4, were shown to be est kindred showed no relationship between the severity of responsible for the disease in six families (16). One large genomic deletion (41 kb) was found in an Ameri- Published online ahead of print. Publication date available at www.jasn.org. can family, and a smaller deletion (22 kb) was found in a French family. Both of the deletions that were found in these unrelated Address correspondence to: Dr. Xavier Jeunemaitre, INSERM U36, College de France 11, Place Marcelin Berthelot, 75005 Paris, France. Phone: ϩ33-0-1-44-27- kindreds were located in the same part of the first intron of the 16-55; Fax: ϩ33-0-1-44-27-16-91; E-mail: [email protected] WNK1 gene. No mutation was identified in the coding se- Copyright © 2006 by the American Society of Nephrology ISSN: 1046-6673/1701-0208 J Am Soc Nephrol 17: 208–217, 2006 Familial Hyperkalemic Hypertension 209 Table 1. Genetic heterogeneity of familial hyperkalemic hypertension Type Transmission Locus Location Gene Reference FHHt1 Dominant PHA2C 12p13.3 WNK1 Wilson et al. (16) FHHt2 Dominant PHA2B 17q21 WNK4 Wilson et al. (16) FHHt3 Dominant PHA2A 1q31-42 ? Mansfield et al. (13) FHHt4 Dominant PHA2D ? ? Disse-Nicodeme et al. (15) quence of the gene. WNK1 is located at the telomeric part of the first and second coiled-coil domains (Figure 1). They result chromosome 12 (12p12.3). It contains 28 exons in a 156-kb in the substitution of a charged residue in these negatively and segment. This segment is particularly large as a result, in part, positively charged sequences (16,17). As coiled-coil domains of the large size (60 kb) of intron 1 (NM_018979.1). Several are generally thought to be involved in protein–protein inter- WNK1 isoforms have been identified (see below). An analysis actions, the mutations may affect the interaction of WNK4 with of WNK1 transcript levels in leukocytes from affected and its partners. unaffected members of one of these FHHt families revealed that the intronic deletion was associated with five times higher levels of its expression (16). WNK Kinase Structure The identification of mutations in WNK1 and knowledge of WNK (with no lysine [K] [18]) proteins form a small family of the existence of a putative PHA2 locus on chromosomes 1 and serine/threonine kinases that were identified by Xu et al. (19). 17 led to the identification of WNK4, located on 17q21-q22. This They lack a conserved lysine that usually is found in subdo- gene contains 18 exons in a 16-kb segment (NM_032387). WNK1 main II of the catalytic domain that is critical for ATP binding and WNK4 have similar sequences and intron-exon organiza- to the catalytic site and strictly conserved in all other serine/ tions, but the WNK4 mutations that were found in several FHHt threonine kinases that have been identified to date. In WNK, kindreds differ considerably from the WNK1 mutations identi- this lysine is replaced by a cysteine, and the catalytic lysine is fied. The WNK4 mutations are missense mutations that affect located in subdomain I. This new subfamily of protein kinases short (approximately 10 amino acids) sequences that are highly has been found only in multicellular organisms. Four members conserved in the WNK family, immediately downstream from of the family have been identified in humans: WNK1, WNK2, Figure 1. Structure of the human WNK4 gene and description of the familial hyperkalemic hypertension (FHHt) missense mutations. The human WNK4 gene is 16 kb long and contains 19 exons. The kinase domain is encoded by exons 1 to 6, the autoinhibitory (AI) domain is encoded by exons 6 to 7. Exons 7 and 17 encode the first (CC1) and second (CC2) coiled-coil domains, respectively, and the adjacent small motifs, where the FHHt missense mutations were found. These 10 and 16 amino acid motifs are conserved among the WNK family. 210 Journal of the American Society of Nephrology J Am Soc Nephrol 17: 208–217, 2006 WNK3, and WNK4, located on 12p13.3, 9q22.31, Xp11.22, and ity. They generated a homology-based structural model of 17p11-q21, respectively (16,20,21). WNK4, using the WNK1 coordinates. They identified two res- New insight recently has been provided into the structure idues, at positions 318 and 448, that differed between the two and function of these kinases. The structure of the kinase do- enzymes and that seemed to mediate stable binding between main of WNK1 has been resolved at a resolution of 1.8 A (22). WNK1 and Syt2. This may account for the poor phosphoryla- This structure has confirmed that the lysine residue that is tion of synaptotagmin 2 by WNK4 in their experiments. Wang responsible for kinase activity is located in strand ␤2 rather et al. (25), using GST fusion constructs, confirmed the capacity than in ␤3 as in other protein kinases and the precise confor- of WNK1 constructs to autophosphorylate and to phosphory- mation of the activation loop and has identified residues that late the generic substrate histone.
Load more

Recommended publications
  • Targeted Genes and Methodology Details for Neuromuscular Genetic Panels
    Targeted Genes and Methodology Details for Neuromuscular Genetic Panels Reference transcripts based on build GRCh37 (hg19) interrogated by Neuromuscular Genetic Panels Next-generation sequencing (NGS) and/or Sanger sequencing is performed Motor Neuron Disease Panel to test for the presence of a mutation in these genes. Gene GenBank Accession Number Regions of homology, high GC-rich content, and repetitive sequences may ALS2 NM_020919 not provide accurate sequence. Therefore, all reported alterations detected ANG NM_001145 by NGS are confirmed by an independent reference method based on laboratory developed criteria. However, this does not rule out the possibility CHMP2B NM_014043 of a false-negative result in these regions. ERBB4 NM_005235 Sanger sequencing is used to confirm alterations detected by NGS when FIG4 NM_014845 appropriate.(Unpublished Mayo method) FUS NM_004960 HNRNPA1 NM_031157 OPTN NM_021980 PFN1 NM_005022 SETX NM_015046 SIGMAR1 NM_005866 SOD1 NM_000454 SQSTM1 NM_003900 TARDBP NM_007375 UBQLN2 NM_013444 VAPB NM_004738 VCP NM_007126 ©2018 Mayo Foundation for Medical Education and Research Page 1 of 14 MC4091-83rev1018 Muscular Dystrophy Panel Muscular Dystrophy Panel Gene GenBank Accession Number Gene GenBank Accession Number ACTA1 NM_001100 LMNA NM_170707 ANO5 NM_213599 LPIN1 NM_145693 B3GALNT2 NM_152490 MATR3 NM_199189 B4GAT1 NM_006876 MYH2 NM_017534 BAG3 NM_004281 MYH7 NM_000257 BIN1 NM_139343 MYOT NM_006790 BVES NM_007073 NEB NM_004543 CAPN3 NM_000070 PLEC NM_000445 CAV3 NM_033337 POMGNT1 NM_017739 CAVIN1 NM_012232 POMGNT2
    [Show full text]
  • Mapping Protein Interactions of Sodium Channel Nav1.7 Using 2 Epitope-Tagged Gene Targeted Mice
    bioRxiv preprint doi: https://doi.org/10.1101/118497; this version posted March 20, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Mapping protein interactions of sodium channel NaV1.7 using 2 epitope-tagged gene targeted mice 3 Alexandros H. Kanellopoulos1†, Jennifer Koenig1, Honglei Huang2, Martina Pyrski3, 4 Queensta Millet1, Stephane Lolignier1, Toru Morohashi1, Samuel J. Gossage1, Maude 5 Jay1, John Linley1, Georgios Baskozos4, Benedikt Kessler2, James J. Cox1, Frank 6 Zufall3, John N. Wood1* and Jing Zhao1†** 7 1Molecular Nociception Group, WIBR, University College London, Gower Street, 8 London WC1E 6BT, UK. 9 2Mass Spectrometry Laboratory, Target Discovery Institute, University of Oxford, The 10 Old Road Campus, Oxford, OX3 7FZ, UK. 11 3Center for Integrative Physiology and Molecular Medicine, Saarland University, 12 Kirrbergerstrasse, Bldg. 48, 66421 Homburg, Germany. 13 4Division of Bioscience, University College London, Gower Street, London WC1E 6BT, UK.14 15 †These authors contributed equally to directing this work. 16 *Correspondence author. Tel: +44 207 6796 954; E-mail: [email protected] 17 **Corresponding author: Tel: +44 207 6790 959; E-mail: [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/118497; this version posted March 20, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 18 Abstract 19 The voltage-gated sodium channel NaV1.7 plays a critical role in pain pathways. 20 Besides action potential propagation, NaV1.7 regulates neurotransmitter release, 21 integrates depolarizing inputs over long periods and regulates transcription.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Mapping Protein Interactions of Sodium Channel
    Published online: January 15, 2018 Resource Mapping protein interactions of sodium channel NaV1.7 using epitope-tagged gene-targeted mice Alexandros H Kanellopoulos1,†, Jennifer Koenig1,†, Honglei Huang2, Martina Pyrski3 , Queensta Millet1, Stéphane Lolignier1,4, Toru Morohashi1, Samuel J Gossage1, Maude Jay1, John E Linley1,5, Georgios Baskozos6 , Benedikt M Kessler2, James J Cox1, Annette C Dolphin7, Frank Zufall3, John N Wood1,* & Jing Zhao1,** Abstract Introduction The voltage-gated sodium channel NaV1.7 plays a critical role in Pain is a major clinical problem. A 2012 National Health Interview pain pathways. We generated an epitope-tagged NaV1.7 mouse Survey (NHIS) in the United States revealed that 25.3 million adults that showed normal pain behaviours to identify channel-inter- (11.2%) suffered from daily (chronic) pain and 23.4 million acting proteins. Analysis of NaV1.7 complexes affinity-purified (10.3%) reported severe pain within a previous 3-month period under native conditions by mass spectrometry revealed 267 (Nahin, 2015). Many types of chronic pain are difficult to treat as proteins associated with Nav1.7 in vivo. The sodium channel b3 most available drugs have limited efficacy and can cause side (Scn3b), rather than the b1 subunit, complexes with Nav1.7, and effects. There is thus a huge unmet need for novel analgesics we demonstrate an interaction between collapsing-response medi- (Woodcock, 2009). Recent human and animal genetic studies have ator protein (Crmp2) and Nav1.7, through which the analgesic drug indicated that the voltage-gated sodium channel (VGSC) NaV1.7 lacosamide regulates Nav1.7 current density. Novel NaV1.7 protein plays a crucial role in pain signalling (Nassar et al, 2004; Cox et al, interactors including membrane-trafficking protein synaptotag- 2006; Dib-Hajj et al, 2013), highlighting NaV1.7 as a promising drug min-2 (Syt2), L-type amino acid transporter 1 (Lat1) and trans- target for development of novel analgesics (Habib et al, 2015; membrane P24-trafficking protein 10 (Tmed10) together with Emery et al, 2016).
    [Show full text]
  • Genes and Symptoms of Schizophrenia: Modifiers, Networks, and Interactions in Complex Disease
    Virginia Commonwealth University VCU Scholars Compass Theses and Dissertations Graduate School 2009 Genes and Symptoms of Schizophrenia: Modifiers, Networks, and Interactions in Complex Disease Sarah Bergen Virginia Commonwealth University Follow this and additional works at: https://scholarscompass.vcu.edu/etd Part of the Medical Genetics Commons © The Author Downloaded from https://scholarscompass.vcu.edu/etd/1940 This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact [email protected]. Genes and Symptoms of Schizophrenia: Modifiers, Networks, and Interactions in Complex Disease A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy at Virginia Commonwealth University by: Sarah E. Bergen B.A., Macalester College, 2000 M.S., University of Pittsburgh, 2004 Director: Kenneth S. Kendler, M.D. Distinguished Professor, Departments of Psychiatry and Human and Molecular Genetics Virginia Commonwealth University Richmond, VA September, 2009 Acknowledgements First, I want to thank my parents whose unconditional love and only slightly conditional support has carried me through every bump and rough patch on my journey through grad school (and life). None of my work would have been accomplished without all you have done for me, and I am profoundly grateful. I have been extremely fortunate in my experiences here to not only have been quite productive scientifically, but also to have enjoyed the graduate school experience. This is almost entirely due to the brilliant and kind people I have had the opportunity to work with.
    [Show full text]
  • Calcium Control of Neurotransmitter Release
    Downloaded from http://cshperspectives.cshlp.org/ on September 27, 2021 - Published by Cold Spring Harbor Laboratory Press Calcium Control of Neurotransmitter Release Thomas C. Su¨dhof Department of Molecular and Cellular Physiology, and Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, California 94305 Correspondence: [email protected] Upon entering a presynaptic terminal, an action potential opens Ca2þ channels, and transiently increases the local Ca2þ concentration at the presynaptic active zone. Ca2þ then triggers neurotransmitter release within a few hundred microseconds by activating synaptotagmins Ca2þ. Synaptotagmins bind Ca2þ via two C2-domains, and transduce the Ca2þ signal into a nanomechanical activation of the membrane fusion machinery; this acti- vation is mediated by the Ca2þ-dependent interaction of the synaptotagmin C2-domains with phospholipids and SNARE proteins. In triggering exocytosis, synaptotagmins do not act alone, but require an obligatory cofactor called complexin, a small protein that binds to SNARE complexes and simultaneously activates and clamps the SNARE complexes, thereby positioning the SNARE complexes for subsequent synaptotagmin action. The con- served function of synaptotagmins and complexins operates generally in most, if not all, Ca2þ-regulated forms of exocytosis throughout the body in addition to synaptic vesicle exo- cytosis, including in the degranulation of mast cells, acrosome exocytosis in sperm cells, hormone secretion from endocrine cells, and neuropeptide release. ynaptic transmission is initiated when an in the brainstem (Fig. 1B; reviewed in Mein- Saction potential invades a nerve terminal, renken et al. 2003). Overall, these high-resolution opening Ca2þ channels, which gate a highly electrophysiological studies on neurotrans- localized, transient increase in intracellular mitter release revealed that a presynaptic action Ca2þ at the active zone (Fig.
    [Show full text]
  • Gangliosides Interact with Synaptotagmin to Form the High-Affinity Receptor Complex for Botulinum Neurotoxin B
    Gangliosides interact with synaptotagmin to form the high-affinity receptor complex for botulinum neurotoxin B Alessandra Floresa,b,1, Jorge Ramirez-Francoa,b,1, Richard Desplantesa,b, Kévin Debreuxa,b, Géraldine Ferraccib,c, Florian Wernerta,b, Marie-Pierre Blanchardb,c, Yves Mauleta,b, Fahamoe Youssoufa,b, Marion Sangiardia,b, Cécile Iborraa,b, Michel Robert Popoffd, Michael Seagara,b, Jacques Fantinia,b, Christian Lévêquea,b, and Oussama El Fara,b,2 aUnité de Neurobiologie des Canaux Ioniques et de la Synapse, INSERM UMR_S 1072, 13015 Marseille, France; bAix-Marseille Université, 13015 Marseille, France; cInstitut de Neurophysiopathologie, CNRS UMR 7051, 13015 Marseille, France; and dBacterial Toxins, Équipe de Recherche Labellisée 6002, Institut Pasteur, 75015 Paris, France Edited by Solomon H. Snyder, Johns Hopkins University School of Medicine, Baltimore, MD, and approved August 1, 2019 (received for review May 15, 2019) Botulinum neurotoxin type B (BoNT/B) recognizes nerve terminals synaptic vesicle proteins that become accessible at the presynaptic by binding to 2 receptor components: a polysialoganglioside, membrane upon exocytosis. BoNT/A and E bind to the synaptic predominantly GT1b, and synaptotagmin 1/2. It is widely thought vesicle protein 2 (SV2), while BoNT/B binds synaptotagmin (SYT that BoNT/B initially binds to GT1b then diffuses in the plane of isoforms 1 and 2). the membrane to interact with synaptotagmin. We have addressed Gangliosides are amphiphilic glycosphingolipid molecules the hypothesis that a GT1b–synaptotagmin cis complex forms the predominantly anchored, via their ceramide group, in the outer BoNT/B receptor. We identified a consensus glycosphingolipid-binding leaflet of plasma membranes. Their extracellular polar part is motif in the extracellular juxtamembrane domain of synaptotagmins composed of several characteristic sugar molecules with the 1/2 and confirmed by Langmuir monolayer, surface plasmon reso- negatively charged sialic acids at precise positions.
    [Show full text]
  • The Molecular Machinery of Neurotransmitter Release Nobel Lecture, 7 December 2013
    The Molecular Machinery of Neurotransmitter Release Nobel Lecture, 7 December 2013 by Thomas C. Südhof Dept. of Molecular and Cellular Physiology, and Howard Hughes Medical Institute, Stanford University, USA. 1. THE NEUROTRANSMITTER RELEASE ENIGMA Synapses have a long history in science. Synapses were frst functionally demon- strated by Emil duBois-Reymond (1818–1896), were morphologically identifed by classical neuroanatomists such as Rudolf von Kölliker (1817–1905) and San- tiago Ramon y Cajal (1852–1934), and named in 1897 by Michael Foster (1836– 1907). Although the chemical nature of synaptic transmission was already sug- gested by duBois-Reymond, it was long disputed because of its incredible speed. Over time, however, overwhelming evidence established that most synapses use chemical messengers called neurotransmitters, most notably with the pioneer- ing contributions by Otto Loewi (1873–1961), Henry Dale (1875–1968), Ulf von Euler (1905–1983), and Julius Axelrod (1912–2004). In parallel, arguably the most important advance to understanding how synapses work was provided by Bernard Katz (1911–2003), who elucidated the principal mechanism of syn- aptic transmission (Katz, 1969). Most initial studies on synapses were carried out on the neuromuscular junction, and central synapses have only come to the fore in recent decades. Here, major contributions by many scientists, including George Palade, Rodolfo Llinas, Chuck Stevens, Bert Sakmann, Eric Kandel, and Victor Whittaker, to name just a few, not only confrmed the principal results obtained in the neuromuscular junction by Katz, but also revealed that synapses 259 6490_Book.indb 259 11/4/14 2:29 PM 260 The Nobel Prizes exhibit an enormous diversity of properties as well as an unexpected capacity for plasticity.
    [Show full text]
  • Development and Characterization of Human Ipsc-Derived Neurons for Drug Discovery Applications
    Development and Characterization of Human iPSC-derived Neurons for Drug Discovery Applications Lucas Chase1, Monica Strathman1, Jeff Grinager1, David Majewski1, Regina Whitemarsh2, Sabine Pellett2, Oksana Sirenko3, Jayne Hesley3, Penny Tavormina3, Casey Stankewicz1, Matt George1, Ning Liu1, Nathan Meyer1, Matthew Riley1, Xuezhu Feng1, Eric Johnson2, Wen Bo Wang1 and Brad Swanson1 1Cellular Dynamics International, Inc., Madison, WI 53711; 2Department of Bacteriology, University of Wisconsin, Madison, WI 53706; 3Molecular Devices, Sunnyvale, CA 94089 Target Target Compound Lead Preclinical Clinical Identification Validation Screening Optimization Trials Trials Abstract Phenotype Characterization Electrophysiology High Content Image-based Assays Cell-based Assays A. B. The human brain represents a complex organ that has A. Evoked Action Potential B. Spontaneous Action Potential A. B. consistently been proven difficult to model in vitro. Current models A. B. 30 20 20 including primary rodent tissue and immortalized cell lines have 10 10 0 0mV served as mainstays in both academic research and the 0 0mV ubulin t -10 - -10 pharmaceutical industry. These models, while providing a means -20 III -20 for numerous landmark discoveries, have suffered from various -30 -30 10mV10mV -40 10mV Figure 10. iCell Neurons display an expected sensitivity to known compounds. iCell Class Class 1sec 5msec 1sec -40 issues including biological relevance, reproducibility and -50 Neurons were cultured for 7-14 days post-thaw on PLO/Laminin pre-coated 96-well plates -60 scalability. Considerable efforts have been made specifically -50 and exposed to a dilution series of (A) staurosporine and (B) kainic acid. Viability (as ® -60 measured using cellular ATP content) was determined using the CellTiter-Glo within the pharmaceutical industry to reduce late-stage drug Nestin Luminescent Cell Viability Assay (Promega).
    [Show full text]
  • Control of Exocytosis by Synaptotagmins and Otoferlin in Auditory Hair Cells
    Control of exocytosis by synaptotagmins and otoferlin in auditory hair cells. Maryline Beurg, Nicolas Michalski, Saaid Safieddine, Yohan Bouleau, Ralf Schneggenburger, Edwin R Chapman, Christine Petit, Didier Dulon To cite this version: Maryline Beurg, Nicolas Michalski, Saaid Safieddine, Yohan Bouleau, Ralf Schneggenburger, et al.. Control of exocytosis by synaptotagmins and otoferlin in auditory hair cells.. Journal of Neuroscience, Society for Neuroscience, 2010, 30 (40), pp.13281-90. 10.1523/JNEUROSCI.2528-10.2010. pasteur- 01472847 HAL Id: pasteur-01472847 https://hal-pasteur.archives-ouvertes.fr/pasteur-01472847 Submitted on 30 Apr 2018 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. The Journal of Neuroscience, October 6, 2010 • 30(40):13281–13290 • 13281 Cellular/Molecular Control of Exocytosis by Synaptotagmins and Otoferlin in Auditory Hair Cells Maryline Beurg,1 Nicolas Michalski,2 Saaid Safieddine,3 Yohan Bouleau,1 Ralf Schneggenburger,2 Edwin R. Chapman,4 Christine Petit,3,5 and Didier Dulon1 1Equipe Neurophysiologie de la Synapse Auditive,
    [Show full text]
  • Patterns of Sequence Conservation in Presynaptic Neural Genes
    University of Pennsylvania ScholarlyCommons Departmental Papers (CIS) Department of Computer & Information Science November 2006 Patterns of Sequence Conservation in Presynaptic Neural Genes Dexter Hadley University of Pennsylvania Tara Murphy University of Pennsylvania Otto Valladares University of Pennsylvania Sridhar Hannenhalli University of Pennsylvania Lyle H. Ungar University of Pennsylvania, [email protected] See next page for additional authors Follow this and additional works at: https://repository.upenn.edu/cis_papers Recommended Citation Dexter Hadley, Tara Murphy, Otto Valladares, Sridhar Hannenhalli, Lyle H. Ungar, Junhyong Kim, and Maja Bucan, "Patterns of Sequence Conservation in Presynaptic Neural Genes", . November 2006. Reprinted from Genome Biology, Volume 7, Issue 11, November 2006, pages R105.1-R105.19. Publisher URL: http://genomebiology.com/2006/7/11/R105 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/cis_papers/282 For more information, please contact [email protected]. Patterns of Sequence Conservation in Presynaptic Neural Genes Abstract Background: The neuronal synapse is a fundamental functional unit in the central nervous system of animals. Because synaptic function is evolutionarily conserved, we reasoned that functional sequences of genes and related genomic elements known to play important roles in neurotransmitter release would also be conserved. Results: Evolutionary rate analysis revealed that presynaptic proteins evolve slowly, although some members of large gene families exhibit accelerated evolutionary rates relative to other family members. Comparative sequence analysis of 46 megabases spanning 150 presynaptic genes identified more than 26,000 elements that are highly conserved in eight vertebrate species, as well as a small subset of sequences (6%) that are shared among unrelated presynaptic genes.
    [Show full text]
  • New Recessive Mutations in SYT2 Causing Severe Presynaptic Congenital Myasthenic Syndromes
    ARTICLE OPEN ACCESS New recessive mutations in SYT2 causing severe presynaptic congenital myasthenic syndromes St´ephanie Bauch´e, PhD, Alain Sureau, PhD, Damien Sternberg, MD, John Rendu, PharmD, PhD, C´eline Buon, Correspondence ´ Julien Mess´eant, PhD, Myriam Bo¨ex, PhD, Denis Furling, PhD, Julien Faur´e, PhD, X´enia Latypova, MD, PhD, Dr. Bauche [email protected] Antoinette Bernabe Gelot, MD, PhD, Mich`ele Mayer, MD, Pierre Mary, MD, Sandra Whalen, MD, Emmanuel Fournier, MD, PhD, Isabelle Cloix, MD, Ganaelle Remerand, MD, Fanny Laffargue, MD, Marie-Christine Nougues, MD, Bertrand Fontaine, MD, PhD, Bruno Eymard, MD, PhD, Arnaud Isapof, MD, and Laure Strochlic, PhD Neurol Genet 2020;6:e534. doi:10.1212/NXG.0000000000000534 Abstract Objective To report the identification of 2 new homozygous recessive mutations in the synaptotagmin 2 (SYT2) gene as the genetic cause of severe and early presynaptic forms of congenital myas- thenic syndromes (CMSs). Methods Next-generation sequencing identified new homozygous intronic and frameshift mutations in the SYT2 gene as a likely cause of presynaptic CMS. We describe the clinical and electro- myographic patient phenotypes, perform ex vivo splicing analyses to characterize the effect of the intronic mutation on exon splicing, and analyze the functional impact of this variation at the neuromuscular junction (NMJ). Results The 2 infants presented a similar clinical phenotype evoking first a congenital myopathy characterized by muscle weakness and hypotonia. Next-generation sequencing allowed to the identification of 1 homozygous intronic mutation c.465+1G>A in patient 1 and another ho- mozygous frameshift mutation c.328_331dup in patient 2, located respectively in the 59 splice donor site of SYT2 intron 4 and in exon 3.
    [Show full text]